Dianthus Therapeutics Inc (DNTH)

Currency in USD
21.50
+0.91(+4.42%)
Closed·
After Hours
21.500.00(0.00%)
·

DNTH Financial Summary

Key Ratios

P/E Ratio-6.46
Price/Book1.77
Debt / Equity0.42%
Return on Equity-28.73%
Dividend Yield0.00%
EBITDA-101.77M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 51.78
(+140.83% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
-0.82 / -0.50
Revenue / Forecast
1.16M / --
EPS Revisions
Last 90 days

FAQ

What were Dianthus Therapeutics's earnings for the latest quarter?

The Dianthus Therapeutics EPS (TTM) is -2.81. Dianthus Therapeutics reported sales of 1.16, net income of -29.51, and EPS of -0.82 for the latest quarter.

What was Dianthus Therapeutics's net income for the latest quarter?

Dianthus Therapeutics's net income for the latest quarter was -29.51.

How did Dianthus Therapeutics's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1.33 in the previous quarter to 1.16 in the latest quarter, and net income moved from -28.44 to -29.51 compared to the previous quarter.

What is Dianthus Therapeutics's net profit margin on a TTM basis?

Dianthus Therapeutics's trailing twelve months (TTM) net profit margin is -1,362.77%.

How does Dianthus Therapeutics's debt to equity ratio compare to industry standards?

Dianthus Therapeutics's total debt-to-equity ratio is 0.42%.

What is Dianthus Therapeutics's return on investment on a TTM basis?

Dianthus Therapeutics's trailing twelve months (TTM) return on investment (ROI) is -28.73%.

Did Dianthus Therapeutics gain or lose cash last quarter?

In the latest quarter, Dianthus Therapeutics's net change in cash was -12.68 million.

What were Dianthus Therapeutics's total assets and liabilities in the latest quarter?

As of the latest quarter, Dianthus Therapeutics reported total assets of 348.58 million and total liabilities of 16.95 million.

How has Dianthus Therapeutics's total revenue grown this year?

Dianthus Therapeutics's total revenue was 1.33 in the previous quarter and 1.16 in the latest quarter.

What is Dianthus Therapeutics's gross margin on a TTM basis?

Dianthus Therapeutics's trailing twelve months (TTM) gross margin is 100.00%.

What was Dianthus Therapeutics's revenue per share for the latest quarter?

Dianthus Therapeutics's revenue per share for the latest quarter was 3.01.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.